Overview

DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to test the hypothesis that DYME is safe and effective as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining the anterior capsule. Secondary objectives are to compare the safety and effectiveness of DYME to that of a smaller dose of the same API.

Phase:

Phase 3

Details

Lead Sponsor:

Aqumen Biopharmaceuticals, N.A.

Treatments:

Ophthalmic Solutions